Konner J et al. |
Phase I clinical, pharmacokinetic, and pharmacodynamic study of KOS-862 (Epothilone D) in patients with advanced solid tumors and lymphoma. |
2012 |
Invest New Drugs |
pmid:22072399
|
Barten DM et al. |
Hyperdynamic microtubules, cognitive deficits, and pathology are improved in tau transgenic mice with low doses of the microtubule-stabilizing agent BMS-241027. |
2012 |
J. Neurosci. |
pmid:22623658
|
Brunden KR et al. |
Brain-penetrant microtubule-stabilizing compounds as potential therapeutic agents for tauopathies. |
2012 |
Biochem. Soc. Trans. |
pmid:22817712
|
Zhang B et al. |
The microtubule-stabilizing agent, epothilone D, reduces axonal dysfunction, neurotoxicity, cognitive deficits, and Alzheimer-like pathology in an interventional study with aged tau transgenic mice. |
2012 |
J. Neurosci. |
pmid:22423084
|
Fournet V et al. |
Both chronic treatments by epothilone D and fluoxetine increase the short-term memory and differentially alter the mood status of STOP/MAP6 KO mice. |
2012 |
J. Neurochem. |
pmid:23013328
|
Monk JP et al. |
A phase 1 study of KOS-862 (Epothilone D) co-administered with carboplatin (Paraplatin®) in patients with advanced solid tumors. |
2012 |
Invest New Drugs |
pmid:21826439
|
Xiong Y et al. |
HDAC6 mutations rescue human tau-induced microtubule defects in Drosophila. |
2013 |
Proc. Natl. Acad. Sci. U.S.A. |
pmid:23487739
|
Cartelli D et al. |
Microtubule alterations occur early in experimental parkinsonism and the microtubule stabilizer epothilone D is neuroprotective. |
2013 |
Sci Rep |
pmid:23670541
|
Wang C et al. |
Molybdenum-based complexes with two aryloxides and a pentafluoroimido ligand: catalysts for efficient Z-selective synthesis of a macrocyclic trisubstituted alkene by ring-closing metathesis. |
2013 |
Angew. Chem. Int. Ed. Engl. |
pmid:23307513
|
Wessjohann LA et al. |
Total synthesis of epothilone D: the nerol/macroaldolization approach. |
2013 |
J. Org. Chem. |
pmid:24079664
|